Mode
Text Size
Log in / Sign up
N/A N=17 Basic Science

Brain Biomarkers of Response to Treatment for Apraxia of Speech

Aphasia · Stroke

Enrolled (actual)
17
Serious AEs
0.0%
Results posted
Aug 2019
Primary outcome: Primary: Change From Baseline in Percent of Trained Items Correctly Repeated — 6.67 d2 treatment effect size

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Speech Production Treatment (Behavioral)
Age
Adult, Older Adult · 40+ yrs
Sex
All
Sponsor
VA Office of Research and Development
Primary completion
Jan 2018

Outcome Measures

OutcomeResultp-value
PRIMARY
Change From Baseline in Percent of Trained Items Correctly Repeated
6.67
PRIMARY
Change From Baseline in Percent of Untrained Items Correctly Repeated
2.66
SECONDARY
Percentage Change in Fractional Anisotropy (FA)
-0.46

Summary

The study will use MRI brain imaging to identify brain changes associated in stroke patients after they receive speech-language treatment for their speech difficulties.

Eligibility Criteria

Inclusion Criteria

  • Inclusion criteria are age 40-90
  • primary English speaker since < age 5
  • a history of a single left hemisphere stroke
  • at least 1 year post-stroke
  • at least 12 years of education
  • pre-morbidly right-handed (Edinburgh Handedness Questionnaire)
  • within normal limits on the Test of Non-Verbal Intelligence

Exclusion Criteria

  • Exclusion criteria will include a pre-morbid neurologic or psychiatric history
  • history/current substance abuse disorder
  • MRI contraindications
  • other motor speech disorders (e.g., dysarthria)
  • current or recent (<2 months) speech/language therapy
  • prior SPT
  • pre-morbid history of speech/language disorders
  • significant hearing disabilities (based on a pure-tone audiological screen at 35 dB HL at 500, 1K, and 2K Hz for at least one ear)
  • aphasia severity resulting in <30th percentile performance on the Porch Index of Communicative Ability-R
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02046941). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search